288 Pharmacokinetics and pharmacodynamics of the novel proteasome inhibitor CEP-18770 during a phase I trial in patients with solid tumor, non-Hodgkin lymphoma or multiple myeloma

✍ Scribed by F. Sala; E. Marangon; D. Brunelli; C. Sessa; E. Dall'Ó; R. Cereda; V. Livi; M. D'Incalci; M. Zucchetti

• Book ID: 119602971
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 48 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)71995-9